Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Perrigo Company PLC receives FDA final approval for generic equivalent to Prandin


Friday, 24 Jan 2014 07:50am EST 

Perrigo Company PLC:Says it has received final approval from the U.S FDA for its abbreviated new drug application (ANDA) for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product.Says Prandin tablets (repaglinide tablets), are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of about $250 mln, as measured by Symphony Health Solutions. 

Company Quote

154.5
0.23 +0.15%
21 Nov 2014